Range of reported outcomes from trials for patients with newly diagnosed multiple myeloma who are transplant ineligible
| Regimen . | Overall response rate, % . | Complete response rate, % . | Median PFS, mo . | Median OS, mo . | 3-y OS in high-risk subset, % . | Early deaths/death due to toxicity, % . | Treatment discontinuation due to adverse events, % . | Grade ≥3 fatigue, % . | Grade ≥3 neuropathy, % . |
|---|---|---|---|---|---|---|---|---|---|
| Proteosome inhibitor based | |||||||||
| VD/VP24,25 | 64-73 | 3-8 | 14.0-14.7 | 49.8 | NR | NR | 29 | 11 | 22 |
| VMP24,25,35,75-78 | 70-86 | 4-30 | 17.1-31 | 74%-87% 3-y OS | 56.1 | 3-6 | 2.3-34 | 2-8 | 7-20 |
| VCD-lite/VCP25,79 | 64-67 | 2-29 | 15.2-24.2 | 29.7 | NR | 7.1-7.9 | 14 | 6.1 | 6.1 |
| Immunomodulatory agent based | |||||||||
| Rd36,41,80-82 | 70-81 | 3-22 | 8.9-25.3 | 30.5-62.3 | NR | 4.6 | 7-19 | 2-11 | 0-2 |
| MPR80,83 | 68 | 3-11 | 14-24 | 62% 3-y OS | NR | 0.7-2.3 | 4-18 | 2-3 | 0-3 |
| MPR+R maintenance83-85 | 70.4-84 | 11.2-16 | 18.7-31 | 69%-70% 3-y OS | NR | 2 | 16-41 | 5 | 0-2 |
| CPR80 | 74 | 0.5 | 20 | 68% 4-y OS | NR | 3.6 | 15 | 2 | 3 |
| Proteosome inhibitor + immunomodulatory agent | |||||||||
| RVD-lite32 | 86 | 44 | 35.1 | NR | NR | NR | 4 | 16 | 2 |
| VMPT-VT78,86 | 89 | 38 | 35.3 | 61% 5-y OS | NR | 4 | 23 | 6 | 16.8 |
| VTD/VTP24,76,77 | 80-81 | 4-28 | 15.4-34 | 43-51.5 | 55 | 5 | 17-38 | 12 | 9-27 |
| Proteosome inhibitor + monoclonal antibody | |||||||||
| VMP-dara35 | 90.9 | 42.6 | NR | NR | NR | 3.2 | 4.9 | NR | 1.4 |
| Regimen . | Overall response rate, % . | Complete response rate, % . | Median PFS, mo . | Median OS, mo . | 3-y OS in high-risk subset, % . | Early deaths/death due to toxicity, % . | Treatment discontinuation due to adverse events, % . | Grade ≥3 fatigue, % . | Grade ≥3 neuropathy, % . |
|---|---|---|---|---|---|---|---|---|---|
| Proteosome inhibitor based | |||||||||
| VD/VP24,25 | 64-73 | 3-8 | 14.0-14.7 | 49.8 | NR | NR | 29 | 11 | 22 |
| VMP24,25,35,75-78 | 70-86 | 4-30 | 17.1-31 | 74%-87% 3-y OS | 56.1 | 3-6 | 2.3-34 | 2-8 | 7-20 |
| VCD-lite/VCP25,79 | 64-67 | 2-29 | 15.2-24.2 | 29.7 | NR | 7.1-7.9 | 14 | 6.1 | 6.1 |
| Immunomodulatory agent based | |||||||||
| Rd36,41,80-82 | 70-81 | 3-22 | 8.9-25.3 | 30.5-62.3 | NR | 4.6 | 7-19 | 2-11 | 0-2 |
| MPR80,83 | 68 | 3-11 | 14-24 | 62% 3-y OS | NR | 0.7-2.3 | 4-18 | 2-3 | 0-3 |
| MPR+R maintenance83-85 | 70.4-84 | 11.2-16 | 18.7-31 | 69%-70% 3-y OS | NR | 2 | 16-41 | 5 | 0-2 |
| CPR80 | 74 | 0.5 | 20 | 68% 4-y OS | NR | 3.6 | 15 | 2 | 3 |
| Proteosome inhibitor + immunomodulatory agent | |||||||||
| RVD-lite32 | 86 | 44 | 35.1 | NR | NR | NR | 4 | 16 | 2 |
| VMPT-VT78,86 | 89 | 38 | 35.3 | 61% 5-y OS | NR | 4 | 23 | 6 | 16.8 |
| VTD/VTP24,76,77 | 80-81 | 4-28 | 15.4-34 | 43-51.5 | 55 | 5 | 17-38 | 12 | 9-27 |
| Proteosome inhibitor + monoclonal antibody | |||||||||
| VMP-dara35 | 90.9 | 42.6 | NR | NR | NR | 3.2 | 4.9 | NR | 1.4 |
CPR, cyclophosphamide, prednisone, and lenalidomide; MPR, melphalan, prednisone, and lenalidomide; MPR+R, melphalan, prednisone, and lenalidomide with lenalidomide maintenance; NR, not reported; OS, overall survival; PFS, progression-free survival. VCD-lite, weekly bortezomib, cyclophosphamide, and dexamethasone; VCD, bortezomib, cyclophosphamide, and dexamethasone; VD, bortezomib and dexamethasone; VMP, bortezomib, melphalan, and prednisone; VMP-dara, bortezomib, melphalan, prednisone, and daratumumab; VMPT-VT, bortezomib, melphalan, prednisone, and thalidomide with bortezomib and thalidomide maintenance; VP, bortezomib and prednisone; VTD, bortezomib, thalidomide, and dexamethasone; VTP, bortezomib, thalidomide, and prednisone.